{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:19:15Z","timestamp":1773213555336,"version":"3.50.1"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82003653"],"award-info":[{"award-number":["No. 82003653"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007128","name":"Natural Science Foundation of Shaanxi Province","doi-asserted-by":"crossref","award":["No. 2024SF-YBXM-482"],"award-info":[{"award-number":["No. 2024SF-YBXM-482"]}],"id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science and Technology Innovative Talent Program of Shaanxi University of Chinese Medicine","award":["No. 2023-KJXX-05"],"award-info":[{"award-number":["No. 2023-KJXX-05"]}]},{"DOI":"10.13039\/501100012105","name":"Huai'an Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["No. 200201011259"],"award-info":[{"award-number":["No. 200201011259"]}],"id":[{"id":"10.13039\/501100012105","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Young Talent fund of University Association for Science and Technology in Shaanxi","award":["No. 20240325"],"award-info":[{"award-number":["No. 20240325"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10822-025-00624-1","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T11:10:05Z","timestamp":1751973005000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Machine learning-based QSAR and structure-based virtual screening guided discovery of novel mIDH1 inhibitors from natural products"],"prefix":"10.1007","volume":"39","author":[{"given":"Hailong","family":"Bai","sequence":"first","affiliation":[]},{"given":"Yalong","family":"Cheng","sequence":"additional","affiliation":[]},{"given":"Shunjiang","family":"Jia","sequence":"additional","affiliation":[]},{"given":"Xiaorui","family":"Wang","sequence":"additional","affiliation":[]},{"given":"Ruyi","family":"Jin","sequence":"additional","affiliation":[]},{"given":"Hui","family":"Guo","sequence":"additional","affiliation":[]},{"given":"Yuping","family":"Tang","sequence":"additional","affiliation":[]},{"given":"Yuwei","family":"Wang","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"issue":"11","key":"624_CR1","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/cr.2010.145","volume":"20","author":"B Yang","year":"2010","unstructured":"Yang B, Zhong C, Peng Y et al (2010) Molecular mechanisms of \u201coff-on switch\u201d of activities of human IDH1 by tumor-associated mutation R132H. Cell Res 20(11):1188\u20131200. https:\/\/doi.org\/10.1038\/cr.2010.145","journal-title":"Cell Res"},{"issue":"12","key":"624_CR2","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1089\/ars.2019.7974","volume":"32","author":"A Scagliola","year":"2020","unstructured":"Scagliola A, Mainini F, Cardaci S (2020) The tricarboxylic acid cycle at the crossroad between cancer and immunity. Antioxid Redox Signal 32(12):834\u2013852. https:\/\/doi.org\/10.1089\/ars.2019.7974","journal-title":"Antioxid Redox Signal"},{"issue":"4","key":"624_CR3","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/annonc\/mdw013","volume":"27","author":"L Dang","year":"2016","unstructured":"Dang L, Yen K, Attar EC (2016) IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol 27(4):599\u2013608. https:\/\/doi.org\/10.1093\/annonc\/mdw013","journal-title":"Ann Oncol"},{"issue":"1","key":"624_CR4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/noajnl\/vdac124","volume":"4","author":"NS Cho","year":"2022","unstructured":"Cho NS, Hagiwara A, Eldred BSC et al (2022) Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas. Neuro-oncol Adv 4(1):124. https:\/\/doi.org\/10.1093\/noajnl\/vdac124","journal-title":"Neuro-oncol Adv"},{"issue":"1","key":"624_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.31557\/apjcp.2024.25.1.317","volume":"25","author":"RA Khairy","year":"2024","unstructured":"Khairy RA, Momtaz EM, Abdelaziz AM, Shibel PE (2024) Evaluation of immunohistochemical expression of ALK-1 in gliomas, WHO grade 4 and its correlation with IDH1-R132H mutation status. Asian Pac J Cancer Prev 25(1):317\u2013323. https:\/\/doi.org\/10.31557\/apjcp.2024.25.1.317","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"624_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3324\/haematol.2023.283732","volume":"109","author":"N Gangat","year":"2024","unstructured":"Gangat N, McCullough K, Abdelmagid M et al (2024) Molecular predictors of response and survival following IDH1\/2 inhibitor monotherapy in acute myeloid leukemia. Haematologica 109(1):187\u2013292. https:\/\/doi.org\/10.3324\/haematol.2023.283732","journal-title":"Haematologica"},{"issue":"8","key":"624_CR7","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/ajh.24072","volume":"90","author":"CD DiNardo","year":"2015","unstructured":"DiNardo CD, Ravandi F, Agresta S et al (2015) Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol 90(8):732\u2013736. https:\/\/doi.org\/10.1002\/ajh.24072","journal-title":"Am J Hematol"},{"key":"624_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/CORR.0000000000002960","author":"G Trovarelli","year":"2024","unstructured":"Trovarelli G, Sbaraglia M, Angelini A et al (2024) Are IDH1 R132 mutations associated with poor prognosis in patients with chondrosarcoma of the bone? Clin Orthop Relat Res. https:\/\/doi.org\/10.1097\/CORR.0000000000002960","journal-title":"Clin Orthop Relat Res"},{"key":"624_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202310208","author":"J Li","year":"2024","unstructured":"Li J, Qin Z, Li Y et al (2024) Phosphorylation of IDH1 facilitates progestin resistance in endometrial cancer. Adv Sci (Weinh). https:\/\/doi.org\/10.1002\/advs.202310208","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"624_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","volume":"17","author":"DR Borger","year":"2012","unstructured":"Borger DR, Tanabe KK, Fan KC et al (2012) Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 17(1):72\u201379. https:\/\/doi.org\/10.1634\/theoncologist.2011-0386","journal-title":"Oncologist"},{"issue":"5897","key":"624_CR11","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1126\/science.1164382","volume":"321","author":"DW Parsons","year":"2008","unstructured":"Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807\u20131812. https:\/\/doi.org\/10.1126\/science.1164382","journal-title":"Science"},{"issue":"4","key":"624_CR12","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.apsb.2022.12.019","volume":"13","author":"Y Liu","year":"2023","unstructured":"Liu Y, Xu W, Li M et al (2023) The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer. Acta Pharm Sin B 13(4):1438\u20131466. https:\/\/doi.org\/10.1016\/j.apsb.2022.12.019","journal-title":"Acta Pharm Sin B"},{"issue":"7","key":"624_CR13","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1158\/2159-8290.CD-13-0083","volume":"3","author":"RA Cairns","year":"2013","unstructured":"Cairns RA, Mak TW (2013) Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov 3(7):730\u2013741. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0083","journal-title":"Cancer Discov"},{"issue":"7274","key":"624_CR14","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature08617","volume":"462","author":"L Dang","year":"2009","unstructured":"Dang L, White DW, Gross S et al (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462(7274):739\u2013744. https:\/\/doi.org\/10.1038\/nature08617","journal-title":"Nature"},{"key":"624_CR15","doi-asserted-by":"publisher","first-page":"982424","DOI":"10.3389\/fphar.2022.982424","volume":"13","author":"W Tian","year":"2022","unstructured":"Tian W, Zhang W, Wang Y et al (2022) Recent advances of IDH1 mutant inhibitor in cancer therapy. Front Pharmacol 13:982424. https:\/\/doi.org\/10.3389\/fphar.2022.982424","journal-title":"Front Pharmacol"},{"issue":"13","key":"624_CR16","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1158\/1078-0432.CCR-21-4462","volume":"28","author":"SJ Casak","year":"2022","unstructured":"Casak SJ, Pradhan S, Fashoyin-Aje LA et al (2022) FDA approval summary: ivosidenib for the treatment of patients with advanced unresectable or metastatic, chemotherapy refractory cholangiocarcinoma with an IDH1 mutation. Clin Cancer Res 28(13):2733\u20132737. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-4462","journal-title":"Clin Cancer Res"},{"issue":"10","key":"624_CR17","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1182\/blood.2022018092","volume":"141","author":"SK Mishra","year":"2023","unstructured":"Mishra SK, Millman SE, Zhang L (2023) Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets. Blood 141(10):1119\u20131135. https:\/\/doi.org\/10.1182\/blood.2022018092","journal-title":"Blood"},{"issue":"4","key":"624_CR18","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1007\/s11030-023-10799-0","volume":"28","author":"M Shafiq","year":"2024","unstructured":"Shafiq M, Sherwani ZA, Mushtaq M et al (2024) A deep learning-based theoretical protocol to identify potentially isoform-selective PI3Kalpha inhibitors. Mol Divers 28(4):1907\u20131924. https:\/\/doi.org\/10.1007\/s11030-023-10799-0","journal-title":"Mol Divers"},{"issue":"12","key":"624_CR19","doi-asserted-by":"publisher","first-page":"e0089523","DOI":"10.1128\/aac.00895-23","volume":"67","author":"F Jiao","year":"2023","unstructured":"Jiao F, Bao Y, Li M et al (2023) Unraveling the mechanism of ceftaroline-induced allosteric regulation in penicillin-binding protein 2a: insights for novel antibiotic development against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 67(12):e0089523. https:\/\/doi.org\/10.1128\/aac.00895-23","journal-title":"Antimicrob Agents Chemother"},{"issue":"20","key":"624_CR20","doi-asserted-by":"publisher","first-page":"7998","DOI":"10.1021\/acs.jcim.4c01206","volume":"64","author":"J Yang","year":"2024","unstructured":"Yang J, Fu B, Gou R et al (2024) Molecular mechanism-driven discovery of novel small molecule inhibitors against drug-resistant SARS-CoV-2 M(pro) variants. J Chem Inf Model 64(20):7998\u20138009. https:\/\/doi.org\/10.1021\/acs.jcim.4c01206","journal-title":"J Chem Inf Model"},{"issue":"4","key":"624_CR21","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1021\/acsmedchemlett.4c00093","volume":"15","author":"H Zhao","year":"2024","unstructured":"Zhao H (2024) The science and art of structure-based virtual screening. ACS Med Chem Lett 15(4):436\u2013440. https:\/\/doi.org\/10.1021\/acsmedchemlett.4c00093","journal-title":"ACS Med Chem Lett"},{"issue":"21","key":"624_CR22","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1021\/acs.jcim.1c00471","volume":"62","author":"M Li","year":"2022","unstructured":"Li M, Li M, Guo J (2022) Molecular mechanism of Ca(2+) in the allosteric regulation of human parathyroid hormone receptor-1. J Chem Inf Model 62(21):5110\u20135119. https:\/\/doi.org\/10.1021\/acs.jcim.1c00471","journal-title":"J Chem Inf Model"},{"key":"624_CR23","doi-asserted-by":"publisher","first-page":"579768","DOI":"10.3389\/fphar.2020.579768","volume":"11","author":"Y Wang","year":"2020","unstructured":"Wang Y, Tang S, Lai H et al (2020) Discovery of novel IDH1 inhibitor through comparative structure-based virtual screening. Front Pharmacol 11:579768. https:\/\/doi.org\/10.3389\/fphar.2020.579768","journal-title":"Front Pharmacol"},{"key":"624_CR24","doi-asserted-by":"publisher","first-page":"982375","DOI":"10.3389\/fphar.2022.982375","volume":"13","author":"C Hu","year":"2022","unstructured":"Hu C, Zeng Z, Ma D et al (2022) Discovery of novel IDH1-R132C inhibitors through structure-based virtual screening. Front Pharmacol 13:982375. https:\/\/doi.org\/10.3389\/fphar.2022.982375","journal-title":"Front Pharmacol"},{"issue":"8","key":"624_CR25","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/s41589-024-01679-1","volume":"20","author":"DB Catacutan","year":"2024","unstructured":"Catacutan DB, Alexander J, Arnold A et al (2024) Machine learning in preclinical drug discovery. Nat Chem Biol 20(8):960\u2013973. https:\/\/doi.org\/10.1038\/s41589-024-01679-1","journal-title":"Nat Chem Biol"},{"issue":"1","key":"624_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41580-021-00407-0","volume":"23","author":"JG Greener","year":"2022","unstructured":"Greener JG, Kandathil SM, Moffat L et al (2022) A guide to machine learning for biologists. Nat Rev Mol Cell Biol 23(1):40\u201355. https:\/\/doi.org\/10.1038\/s41580-021-00407-0","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"20","key":"624_CR27","doi-asserted-by":"publisher","first-page":"9833","DOI":"10.1080\/07391102.2021.1936179","volume":"40","author":"R Kumari","year":"2022","unstructured":"Kumari R, Dalal V (2022) Identification of potential inhibitors for LLM of Staphylococcus aureus: structure-based pharmacophore modeling, molecular dynamics, and binding free energy studies. J Biomol Struct Dyn 40(20):9833\u20139847. https:\/\/doi.org\/10.1080\/07391102.2021.1936179","journal-title":"J Biomol Struct Dyn"},{"key":"624_CR28","doi-asserted-by":"publisher","first-page":"132476","DOI":"10.1016\/j.molstruc.2022.132476","volume":"1255","author":"R Kumari","year":"2022","unstructured":"Kumari R, Rathi R, Pathak SR et al (2022) Structural-based virtual screening and identification of novel potent antimicrobial compounds against YsxC of Staphylococcus aureus. J Mol Struct 1255:132476. https:\/\/doi.org\/10.1016\/j.molstruc.2022.132476","journal-title":"J Mol Struct"},{"key":"624_CR29","unstructured":"Collection of Open Natural Products (2024) https:\/\/coconut.naturalproducts.net\/. accessed 25 Mar 2024"},{"issue":"14","key":"624_CR30","doi-asserted-by":"publisher","first-page":"6575","DOI":"10.1021\/acs.jmedchem.9b00362","volume":"62","author":"J Lin","year":"2019","unstructured":"Lin J, Lu W, Caravella JA et al (2019) Discovery and optimization of quinolinone derivatives as potent, selective, and orally bioavailable mutant isocitrate dehydrogenase 1 (mIDH1) inhibitors. J Med Chem 62(14):6575\u20136596. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b00362","journal-title":"J Med Chem"},{"key":"624_CR31","doi-asserted-by":"publisher","first-page":"105569","DOI":"10.1016\/j.bioorg.2021.105569","volume":"119","author":"X Zhou","year":"2022","unstructured":"Zhou X, Zheng M, Zhao N et al (2022) Discovery of linear unnatural peptides as potent mutant isocitrate dehydrogenase 1 inhibitors by Ugi reaction. Bioorg Chem 119:105569. https:\/\/doi.org\/10.1016\/j.bioorg.2021.105569","journal-title":"Bioorg Chem"},{"issue":"24","key":"624_CR32","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.1016\/j.bmc.2017.10.009","volume":"25","author":"T Ma","year":"2017","unstructured":"Ma T, Zou F, Pusch S et al (2017) Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1. Bioorg Med Chem 25(24):6379\u20136387. https:\/\/doi.org\/10.1016\/j.bmc.2017.10.009","journal-title":"Bioorg Med Chem"},{"issue":"4","key":"624_CR33","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.bmc.2018.12.029","volume":"27","author":"X Liu","year":"2019","unstructured":"Liu X, Hu Y, Gao A et al (2019) Synthesis and biological evaluation of 3-aryl-4-indolyl-maleimides as potent mutant isocitrate dehydrogenase-1 inhibitors. Bioorg Med Chem 27(4):589\u2013603. https:\/\/doi.org\/10.1016\/j.bmc.2018.12.029","journal-title":"Bioorg Med Chem"},{"issue":"8","key":"624_CR34","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1021\/acs.jmedchem.1c00019","volume":"64","author":"JM Rohde","year":"2021","unstructured":"Rohde JM, Karavadhi S, Pragani R et al (2021) Discovery and optimization of 2H\u20131\u03bb(2)-pyridin-2-one inhibitors of mutant isocitrate dehydrogenase 1 for the treatment of cancer. J Med Chem 64(8):4913\u20134946. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00019","journal-title":"J Med Chem"},{"key":"624_CR35","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ejmech.2016.04.066","volume":"119","author":"SK Chitneni","year":"2016","unstructured":"Chitneni SK, Reitman ZJ, Gooden DM et al (2016) Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs. Eur J Med Chem 119:218\u2013230. https:\/\/doi.org\/10.1016\/j.ejmech.2016.04.066","journal-title":"Eur J Med Chem"},{"issue":"4","key":"624_CR36","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1021\/acsmedchemlett.7b00421","volume":"9","author":"J Popovici-Muller","year":"2018","unstructured":"Popovici-Muller J, Lemieux RM, Artin E et al (2018) Discovery of AG-120 (Ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett 9(4):300\u2013305. https:\/\/doi.org\/10.1021\/acsmedchemlett.7b00421","journal-title":"ACS Med Chem Lett"},{"key":"624_CR37","unstructured":"Davis M, Pragani R, Popovici-Muller J et al (2010) ML309: A potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells. In Probe Reports from the NIH Molecular Libraries Program, National Center for Biotechnology Information (US): Bethesda (MD)"},{"issue":"24","key":"624_CR38","doi-asserted-by":"publisher","first-page":"11120","DOI":"10.1021\/acs.jmedchem.6b01320","volume":"59","author":"S Jones","year":"2016","unstructured":"Jones S, Ahmet J, Ayton K et al (2016) Discovery and optimization of allosteric inhibitors of mutant isocitrate dehydrogenase 1 (R132H IDH1) displaying activity in human acute myeloid leukemia cells. J Med Chem 59(24):11120\u201311137. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b01320","journal-title":"J Med Chem"},{"issue":"10","key":"624_CR39","doi-asserted-by":"publisher","first-page":"e1800039","DOI":"10.1002\/ardp.201800039","volume":"351","author":"Y Hu","year":"2018","unstructured":"Hu Y, Gao A, Liao H et al (2018) 3-(7-Azaindolyl)-4-indolylmaleimides as a novel class of mutant isocitrate dehydrogenase-1 inhibitors: design, synthesis, and biological evaluation. Arch Pharm 351(10):e1800039. https:\/\/doi.org\/10.1002\/ardp.201800039","journal-title":"Arch Pharm"},{"issue":"4","key":"624_CR40","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1021\/acsmedchemlett.2c00089","volume":"13","author":"C Huang","year":"2022","unstructured":"Huang C, Fischer C, Machacek MR et al (2022) Diminishing GSH-adduct formation of tricyclic diazepine-based mutant IDH1 inhibitors. ACS Med Chem Lett 13(4):734\u2013741. https:\/\/doi.org\/10.1021\/acsmedchemlett.2c00089","journal-title":"ACS Med Chem Lett"},{"issue":"9","key":"624_CR41","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.21873\/anticanres.14496","volume":"40","author":"CH Kang","year":"2020","unstructured":"Kang CH, Choi SU, Son YH et al (2020) Discovery of a novel chemical scaffold against mutant isocitrate dehydrogenase 1 (IDH1). Anticancer Res 40(9):4929\u20134935. https:\/\/doi.org\/10.21873\/anticanres.14496","journal-title":"Anticancer Res"},{"key":"624_CR42","doi-asserted-by":"publisher","first-page":"116095","DOI":"10.1016\/j.bmc.2021.116095","volume":"36","author":"Y Yang","year":"2021","unstructured":"Yang Y, Xiang K, Sun D et al (2021) Withanolides from dietary tomatillo suppress HT1080 cancer cell growth by targeting mutant IDH1. Bioorg Med Chem 36:116095. https:\/\/doi.org\/10.1016\/j.bmc.2021.116095","journal-title":"Bioorg Med Chem"},{"key":"624_CR43","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.bioorg.2018.04.016","volume":"79","author":"M Zheng","year":"2018","unstructured":"Zheng M, Tang R, Deng Y et al (2018) Steroids from Ganoderma sinense as new natural inhibitors of cancer-associated mutant IDH1. Bioorg Chem 79:89\u201397. https:\/\/doi.org\/10.1016\/j.bioorg.2018.04.016","journal-title":"Bioorg Chem"},{"issue":"23\u201324","key":"624_CR44","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.1016\/j.bmcl.2018.07.002","volume":"28","author":"Q Zheng","year":"2018","unstructured":"Zheng Q, Chen Z, Wan H et al (2018) Discovery and structure-activity-relationship study of novel imidazole cyclopropyl amine analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors. Bioorg Med Chem Lett 28(23\u201324):3808\u20133812. https:\/\/doi.org\/10.1016\/j.bmcl.2018.07.002","journal-title":"Bioorg Med Chem Lett"},{"issue":"23","key":"624_CR45","doi-asserted-by":"publisher","first-page":"5262","DOI":"10.1016\/j.bmcl.2017.10.029","volume":"27","author":"Q Zheng","year":"2017","unstructured":"Zheng Q, Tang S, Fu X et al (2017) Discovery and structure-activity-relationship study of novel conformationally restricted indane analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors. Bioorg Med Chem Lett 27(23):5262\u20135266. https:\/\/doi.org\/10.1016\/j.bmcl.2017.10.029","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"624_CR46","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1021\/acs.jmedchem.9b01423","volume":"63","author":"JA Caravella","year":"2020","unstructured":"Caravella JA, Lin J, Diebold RB et al (2020) Structure-based design and identification of FT-2102 (olutasidenib), a potent mutant-selective IDH1 inhibitor. J Med Chem 63(4):1612\u20131623. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01423","journal-title":"J Med Chem"},{"key":"624_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28052315","author":"M Thamim","year":"2023","unstructured":"Thamim M, Agrahari AK, Gupta P et al (2023) Rational computational approaches in drug discovery: potential inhibitors for allosteric regulation of mutant isocitrate dehydrogenase-1 enzyme in cancers. Molecules. https:\/\/doi.org\/10.3390\/molecules28052315","journal-title":"Molecules"},{"issue":"10","key":"624_CR48","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1021\/ml300225h","volume":"3","author":"J Popovici-Muller","year":"2012","unstructured":"Popovici-Muller J, Saunders JO, Salituro FG et al (2012) Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo. ACS Med Chem Lett 3(10):850\u2013855. https:\/\/doi.org\/10.1021\/ml300225h","journal-title":"ACS Med Chem Lett"},{"key":"624_CR49","doi-asserted-by":"publisher","first-page":"111694","DOI":"10.1016\/j.ejmech.2019.111694","volume":"183","author":"H Cao","year":"2019","unstructured":"Cao H, Zhu G, Sun L et al (2019) Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration. Eur J Med Chem 183:111694. https:\/\/doi.org\/10.1016\/j.ejmech.2019.111694","journal-title":"Eur J Med Chem"},{"key":"624_CR50","doi-asserted-by":"publisher","DOI":"10.1080\/14786419.2023.2269462","author":"X Li","year":"2023","unstructured":"Li X, Shen W, Li G et al (2023) Alternaphenol B2, a new IDH1 inhibitor from the coral-derived fungus Parengyodontium album SCSIO SX7W11. Nat Product Res. https:\/\/doi.org\/10.1080\/14786419.2023.2269462","journal-title":"Nat Product Res"},{"issue":"7","key":"624_CR51","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1021\/acsmedchemlett.8b00182","volume":"9","author":"Q Zhao","year":"2018","unstructured":"Zhao Q, Manning JR, Sutton J et al (2018) Optimization of 3-pyrimidin-4-yl-oxazolidin-2-ones as orally bioavailable and brain penetrant mutant IDH1 inhibitors. ACS Med Chem Lett 9(7):746\u2013751. https:\/\/doi.org\/10.1021\/acsmedchemlett.8b00182","journal-title":"ACS Med Chem Lett"},{"issue":"10","key":"624_CR52","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1021\/acsmedchemlett.6b00264","volume":"7","author":"JM Law","year":"2016","unstructured":"Law JM, Stark SC, Liu K et al (2016) Discovery of 8-membered ring sulfonamides as inhibitors of oncogenic mutant isocitrate dehydrogenase 1. ACS Med Chem Lett 7(10):944\u2013949. https:\/\/doi.org\/10.1021\/acsmedchemlett.6b00264","journal-title":"ACS Med Chem Lett"},{"issue":"2","key":"624_CR53","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1021\/acsmedchemlett.6b00334","volume":"8","author":"JR Levell","year":"2017","unstructured":"Levell JR, Caferro T, Chenail G et al (2017) Optimization of 3-pyrimidin-4-yl-oxazolidin-2-ones as allosteric and mutant specific inhibitors of IDH1. ACS Med Chem Lett 8(2):151\u2013156. https:\/\/doi.org\/10.1021\/acsmedchemlett.6b00334","journal-title":"ACS Med Chem Lett"},{"issue":"15","key":"624_CR54","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1016\/j.bmc.2019.05.040","volume":"27","author":"Z Duan","year":"2019","unstructured":"Duan Z, Liu J, Niu L et al (2019) Discovery of DC_H31 as potential mutant IDH1 inhibitor through NADPH-based high throughput screening. Bioorg Med Chem 27(15):3229\u20133236. https:\/\/doi.org\/10.1016\/j.bmc.2019.05.040","journal-title":"Bioorg Med Chem"},{"key":"624_CR55","doi-asserted-by":"publisher","first-page":"115411","DOI":"10.1016\/j.ejmech.2023.115411","volume":"256","author":"Q Liang","year":"2023","unstructured":"Liang Q, Wang B, Zou F et al (2023) Structure-based discovery of IHMT-IDH1\u2013053 as a potent irreversible IDH1 mutant selective inhibitor. Eur J Med Chem 256:115411. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115411","journal-title":"Eur J Med Chem"},{"key":"624_CR56","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.bbrc.2021.02.112","volume":"551","author":"N Zhang","year":"2021","unstructured":"Zhang N, Zheng B, Yao X et al (2021) Identification and characterization of a novel mutant isocitrate dehydrogenase 1 inhibitor for glioma treatment. Biochem Biophys Res Commun 551:38\u201345. https:\/\/doi.org\/10.1016\/j.bbrc.2021.02.112","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"624_CR57","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1021\/acsmedchemlett.7b00342","volume":"8","author":"YS Cho","year":"2017","unstructured":"Cho YS, Levell JR, Liu G et al (2017) Discovery and evaluation of clinical candidate IDH305, a brain penetrant mutant IDH1 inhibitor. ACS Med Chem Lett 8(10):1116\u20131121. https:\/\/doi.org\/10.1021\/acsmedchemlett.7b00342","journal-title":"ACS Med Chem Lett"},{"issue":"2","key":"624_CR58","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1021\/acsmedchemlett.9b00509","volume":"11","author":"Z Konteatis","year":"2020","unstructured":"Konteatis Z, Artin E, Nicolay B et al (2020) Vorasidenib (AG-881): a first-in-class, brain-penetrant dual inhibitor of mutant IDH1 and 2 for treatment of glioma. ACS Med Chem Lett 11(2):101\u2013107. https:\/\/doi.org\/10.1021\/acsmedchemlett.9b00509","journal-title":"ACS Med Chem Lett"},{"issue":"20","key":"624_CR59","doi-asserted-by":"publisher","first-page":"13717","DOI":"10.1074\/jbc.M113.511030","volume":"289","author":"MI Davis","year":"2014","unstructured":"Davis MI, Gross S, Shen M et al (2014) Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1. J Biol Chem 289(20):13717\u201313725. https:\/\/doi.org\/10.1074\/jbc.M113.511030","journal-title":"J Biol Chem"},{"issue":"4","key":"624_CR60","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00401-017-1677-y","volume":"133","author":"S Pusch","year":"2017","unstructured":"Pusch S, Krausert S, Fischer V et al (2017) Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. Acta Neuropathol 133(4):629\u2013644. https:\/\/doi.org\/10.1007\/s00401-017-1677-y","journal-title":"Acta Neuropathol"},{"issue":"42","key":"624_CR61","doi-asserted-by":"publisher","first-page":"6835","DOI":"10.1038\/s41388-019-0929-9","volume":"38","author":"M Nakagawa","year":"2019","unstructured":"Nakagawa M, Nakatani F, Matsunaga H et al (2019) Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma. Oncogene 38(42):6835\u20136849. https:\/\/doi.org\/10.1038\/s41388-019-0929-9","journal-title":"Oncogene"},{"issue":"27","key":"624_CR62","doi-asserted-by":"publisher","first-page":"44255","DOI":"10.18632\/oncotarget.17464","volume":"8","author":"M Zheng","year":"2017","unstructured":"Zheng M, Sun W, Gao S et al (2017) Structure based discovery of clomifene as a potent inhibitor of cancer-associated mutant IDH1. Oncotarget 8(27):44255\u201344265. https:\/\/doi.org\/10.18632\/oncotarget.17464","journal-title":"Oncotarget"},{"issue":"1","key":"624_CR63","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/carcin\/bgy159","volume":"40","author":"S Verdura","year":"2019","unstructured":"Verdura S, Cuy\u00e0s E, Lozano-S\u00e1nchez J et al (2019) An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors. Carcinogenesis 40(1):27\u201340. https:\/\/doi.org\/10.1093\/carcin\/bgy159","journal-title":"Carcinogenesis"},{"issue":"2","key":"624_CR64","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/s41375-019-0582-x","volume":"34","author":"A Chaturvedi","year":"2020","unstructured":"Chaturvedi A, Goparaju R, Gupta C et al (2020) In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site. Leukemia 34(2):416\u2013426. https:\/\/doi.org\/10.1038\/s41375-019-0582-x","journal-title":"Leukemia"},{"key":"624_CR65","unstructured":"National Center for Biotechnology Information. \"PubChem Bioassay Record for AID 623980, Source: National Center for Advancing Translational Sciences (NCATS)\" PubChem (2024) https:\/\/pubchem.ncbi.nlm.nih.gov\/bioassay\/623980 accessed 1 Aug 2024"},{"key":"624_CR66","unstructured":"Caferro TR, Chen Z, Cho YS et al (2014) 3-Pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutaNT IDH. EP2970240(B1), 2014-03-12"},{"issue":"12","key":"624_CR67","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s10822-007-9133-z","volume":"21","author":"JC Shelley","year":"2007","unstructured":"Shelley JC, Cholleti A, Frye LL et al (2007) Epik: a software program for pK( a ) prediction and protonation state generation for drug-like molecules. J Comput Aided Mol Des 21(12):681\u2013691. https:\/\/doi.org\/10.1007\/s10822-007-9133-z","journal-title":"J Comput Aided Mol Des"},{"key":"624_CR68","unstructured":"Protein Data Bank (2024) http:\/\/www.rcsb.org accessed 15 July 2024"},{"issue":"4","key":"624_CR69","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1021\/acs.jctc.9b00054","volume":"15","author":"MJ Robertson","year":"2019","unstructured":"Robertson MJ, Qian Y, Robinson MC et al (2019) Development and testing of the OPLS-AA\/M force field for RNA. J Chem Theory Comput 15(4):2734\u20132742. https:\/\/doi.org\/10.1021\/acs.jctc.9b00054","journal-title":"J Chem Theory Comput"},{"issue":"7","key":"624_CR70","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1021\/jm030644s","volume":"47","author":"TA Halgren","year":"2004","unstructured":"Halgren TA, Murphy RB, Friesner RA et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47(7):1750\u20131759. https:\/\/doi.org\/10.1021\/jm030644s","journal-title":"J Med Chem"},{"issue":"15","key":"624_CR71","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.4155\/fmc-2016-0093","volume":"8","author":"SL Dixon","year":"2016","unstructured":"Dixon SL, Duan J, Smith E et al (2016) AutoQSAR: an automated machine learning tool for best-practice quantitative structure\u2013activity relationship modeling. Future Med Chem 8(15):1825\u20131839. https:\/\/doi.org\/10.4155\/fmc-2016-0093","journal-title":"Future Med Chem"},{"issue":"16","key":"624_CR72","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/jcc.10128","volume":"23","author":"A Jakalian","year":"2002","unstructured":"Jakalian A, Jack DB, Bayly CI (2002) Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation. J Comput Chem 23(16):1623\u20131641. https:\/\/doi.org\/10.1002\/jcc.10128","journal-title":"J Comput Chem"},{"issue":"16","key":"624_CR73","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/jcc.20290","volume":"26","author":"DA Case","year":"2005","unstructured":"Case DA, Cheatham TE, Darden T et al (2005) The Amber biomolecular simulation programs. J Comput Chem 26(16):1668\u20131688. https:\/\/doi.org\/10.1002\/jcc.20290","journal-title":"J Comput Chem"},{"issue":"9","key":"624_CR74","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/jcc.20035","volume":"25","author":"J Wang","year":"2004","unstructured":"Wang J, Wolf RM, Caldwell JW et al (2004) Development and testing of a general amber force field. J Comput Chem 25(9):1157\u20131174. https:\/\/doi.org\/10.1002\/jcc.20035","journal-title":"J Comput Chem"},{"issue":"8","key":"624_CR75","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","volume":"11","author":"JA Maier","year":"2015","unstructured":"Maier JA, Martinez C, Kasavajhala K et al (2015) ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput 11(8):3696\u20133713. https:\/\/doi.org\/10.1021\/acs.jctc.5b00255","journal-title":"J Chem Theory Comput"},{"issue":"7","key":"624_CR76","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1021\/ct400341p","volume":"9","author":"DR Roe","year":"2013","unstructured":"Roe DR, Cheatham TE (2013) PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput 9(7):3084\u20133095. https:\/\/doi.org\/10.1021\/ct400341p","journal-title":"J Chem Theory Comput"},{"key":"624_CR77","doi-asserted-by":"publisher","DOI":"10.1002\/slct.202201728","author":"V Dalal","year":"2022","unstructured":"Dalal V, Kumari R (2022) Screening and identification of natural product-like compounds as pote ntial antibacterial agents targeting FemC of Staphylococcus aureus: an in-silico approach. ChemistrySelect. https:\/\/doi.org\/10.1002\/slct.202201728","journal-title":"ChemistrySelect"},{"key":"624_CR78","doi-asserted-by":"publisher","unstructured":"Hunter JD (2007) Computing in Science & Engineering. 9(3):90\u201395. https:\/\/doi.org\/10.5281\/zennodo.592536","DOI":"10.5281\/zennodo.592536"},{"key":"624_CR79","unstructured":"Accelrys Software Inc., S. D., CA, USA. https:\/\/accelrys-discovery-studio-visualizer.software.informer.com\/3.0\/"},{"issue":"23","key":"624_CR80","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1093\/bioinformatics\/btq566","volume":"26","author":"RC Lua","year":"2010","unstructured":"Lua RC, Lichtarge O (2010) PyETV: a PyMOL evolutionary trace viewer to analyze functional site predictions in protein complexes. Bioinformatics 26(23):2981\u20132982. https:\/\/doi.org\/10.1093\/bioinformatics\/btq566","journal-title":"Bioinformatics"},{"issue":"2","key":"624_CR81","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1006\/jmbi.1999.3371","volume":"295","author":"H Gohlke","year":"2000","unstructured":"Gohlke H, Hendlich M, Klebe G (2000) Knowledge-based scoring function to predict protein\u2013ligand interactions. J Mol Biol 295(2):337\u2013356. https:\/\/doi.org\/10.1006\/jmbi.1999.3371","journal-title":"J Mol Biol"},{"issue":"11","key":"624_CR82","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/nrd1549","volume":"3","author":"DB Kitchen","year":"2004","unstructured":"Kitchen DB, Decornez H, Furr JR et al (2004) Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov 3(11):935\u2013949. https:\/\/doi.org\/10.1038\/nrd1549","journal-title":"Nat Rev Drug Discov"},{"issue":"W1","key":"624_CR83","doi-asserted-by":"publisher","first-page":"W5","DOI":"10.1093\/nar\/gkab255","volume":"49","author":"G Xiong","year":"2021","unstructured":"Xiong G, Wu Z, Yi J et al (2021) ADMETlab 20: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res 49(W1):W5\u2013W14. https:\/\/doi.org\/10.1093\/nar\/gkab255","journal-title":"Nucleic Acids Res"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-025-00624-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-025-00624-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-025-00624-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:56:59Z","timestamp":1762451819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10822-025-00624-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["624"],"URL":"https:\/\/doi.org\/10.1007\/s10822-025-00624-1","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"value":"0920-654X","type":"print"},{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}